PAPER Burns JM, Honea RA, Vidoni ED, Hutfles L, Brooks WM, Swerdlow RH
SEARCH RESULTS
330907 RESULTS
PAPER Cantin S, Villien M, Moreaud O, Tropres I, Keignart S, Chipon E, Le Bas JF, Warnking J, Krainik A
Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI.
Neuroimage. 2011 Sep 15;58(2):579-87. PubMed: 21745581PAPER Saxena S, Caroni P
Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration.
Neuron. 2011 Jul 14;71(1):35-48. PubMed: 21745636PAPER Tang JX, Mardini F, Caltagarone BM, Garrity ST, Li RQ, Bianchi SL, Gomes O, Laferla FM, Eckenhoff RG, Eckenhoff MF
Anesthesia in presymptomatic Alzheimer's disease: a study using the triple-transgenic mouse model.
Alzheimers Dement. 2011 Sep;7(5):521-531.e1. PubMed: 21745760PAPER Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
Alzheimers Dement. 2011 Nov;7(6):602-610.e2. Epub 2011 Jul 13 PubMed: 21745761PAPER Mossello E, Ballini E, Boncinelli M, Monami M, Lonetto G, Mello AM, Tarantini F, Baldasseroni S, Mannucci E, Marchionni N
Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities.
Exp Diabetes Res. 2011;2011:281674. PubMed: 21747826PAPER Yao J, Chen S, Mao Z, Cadenas E, Brinton RD
2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease.
PLoS One. 2011;6(7):e21788. PubMed: 21747957PAPER Dai L, Liu D, Guo H, Wang Y, Bai Y
Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis.
J Neurol. 2011 Jul 12; PubMed: 21748280PAPER Neugroschl J, Wang S
Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity.
Mt Sinai J Med. 2011 Jul-Aug;78(4):596-612. PubMed: 21748748PAPER Amtul Z, Uhrig M, Beyreuther K
Additive effects of fatty acid mixtures on the levels and ratio of amyloid β40/42 peptides differ from the effects of individual fatty acids.
J Neurosci Res. 2011 Nov;89(11):1795-801. PubMed: 21748777PAPER Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC
Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility.
Genet Test Mol Biomarkers. 2011 Dec;15(12):871-5. PubMed: 21749214PAPER Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J
Targeting amyloid-beta by glucagon-like peptide-1 (GLP-1) in Alzheimer's disease and diabetes.
Expert Opin Ther Targets. 2011 Oct;15(10):1153-62. PubMed: 21749267PAPER Dhawan S, Kapil R, Singh B
Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery.
J Pharm Pharmacol. 2011 Mar;63(3):342-51. PubMed: 21749381PAPER Dachsel JC, Wider C, Vilariño-Güell C, Aasly JO, Rajput A, Rajput AH, Lynch T, Craig D, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu RM, Heckman MG, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA
Death-associated protein kinase 1 variation and Parkinson's disease.
Eur J Neurol. 2011 Aug;18(8):1090-3. PubMed: 21749573PAPER Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins RN, Masters CL, Rowe CC, Szoeke C, Taddei K, Ellis KA,
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing.
Int Psychogeriatr. 2012 Feb;24(2):197-204. PubMed: 21749739Current Filters
No filters selected